I do have concerns about igf 1 as a competitor, but i do not really understand the science.
The fact so many experts in autism have joined such as Joe Horrigan suggests to me there is a difference and probably a meaningful one as the numerous peolpe who have joined the company do understand the science.
Would these experts have joined if igf 1 was going to win the race? It would have been obvious to them if the answer was yes.
Wider autism efficacy potential for nnz-2566, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.550(3.71%) |
Mkt cap ! $1.915B | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.50 | $14.91 | $9.641M | 631.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $15.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1224 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |